Non-Cystic Fibrosis Bronchiectasis Market to Showcase Growth at a Minimal CAGR of 2.8% During the Study Period (2019-2032), Assesses DelveInsight
The non-cystic fibrosis bronchiectasis (NCFB) market size is anticipated to increase during the forecast period (2023–2032) owing to the increasing awareness and increasing diagnosed prevalent population. Moreover, the expected launch of emerging therapies by leading companies, including AstraZeneca,
Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report
- As per DelveInsight analysis, the non-cystic fibrosis bronchiectasis market size in the 7MM +
China was approximatelyUSD 3.4 billion in 2022. - According to the assessment done by DelveInsight, the estimated total diagnosed prevalent non-cystic fibrosis bronchiectasis cases in the 7MM +
China were approximately 9.3 million in 2022. - Leading non-cystic fibrosis bronchiectasis companies such as Insmed Incorporated, AstraZeneca, Zambon,
CSL Behring ,Chiesi Farmaceutici ,Boehringer Ingelheim , Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others are developing novel non-cystic fibrosis bronchiectasis drugs that can be available in the non-cystic fibrosis bronchiectasis market in the coming years. - The promising non-cystic fibrosis bronchiectasis therapies in the pipeline include Brensocatib, Colistimethate sodium, CSL787,
CHF 6333 , BI 1291583, AP-PA02, ARINA-1, S-1226, HSK31858, and others.
Discover which therapies are expected to grab the major non-cystic fibrosis bronchiectasis market share @ Non-Cystic Fibrosis Bronchiectasis Market Report
Non-Cystic Fibrosis Bronchiectasis Overview
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory lung disease. It is distinguished by chronic dilatation of the bronchial tree, which results in chronic sputum production and impaired bacterial clearance. The affected lungs develop a vicious cycle of pathogen clearance failure, resulting in frequent infections, chronic inflammation, and ongoing structural damage. Coughing, sputum production, and frequent respiratory infections are the most common non-cystic fibrosis bronchiectasis symptoms.
Patients frequently experience recurring chest infections. Non-cystic fibrosis bronchiectasis symptom severity can vary greatly. Some people have only a few symptoms that appear infrequently, whereas others have a wide range of daily symptoms. If the patient experiences an exacerbation, the symptoms tend to worsen (usually caused by a chest infection). NCFB has a multifactorial etiology, with a high percentage of cases associated with idiopathic, post-infective, COPD, asthma, and other etiologies.
Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation
DelveInsight estimates that there were approximately 9.3 million diagnosed prevalent cases of non-cystic fibrosis bronchiectasis in the 7MM +
As per the analysis,
The non-cystic fibrosis bronchiectasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- NCFB diagnosed prevalent cases
- NCFB gender-specific cases
- NCFB severity-specific cases
- NCFB etiology-associated cases
- Microbiology of NCFB patients
Download the report to understand which factors are driving non-cystic fibrosis bronchiectasis epidemiology trends @ NCFB Epidemiological Insights
Non-Cystic Fibrosis Bronchiectasis Treatment Market
The current non-cystic fibrosis bronchiectasis treatment regimen include antibiotics, corticosteroids, bronchodilators, acid suppression medication, active mucous agents, and bronchial hygiene measures. The presence of neutrophils in the airway lumen suggests a role for anti-inflammatory therapy in this disease. Corticosteroids and macrolides are two classes of anti-inflammatories that are commonly used. However, it is a universal truth that no single non-cystic fibrosis bronchiectasis treatment approach is appropriate for all NCFB patients.
Inhaled antibiotics are generally thought to be more effective and safer than oral and intravenous antibiotics; however, there are differences of opinion on the subject. While interventions reduce the number of exacerbations, sputum production, and bacterial load in the airways, they also cause more localized side effects that can lead to withdrawal. Furthermore, comparative trials on inhaled antibiotics are limited and contentious due to bias in population selection and methodological variability. Moreover, inhaled corticosteroids (ICS) have also been studied in NCFB, with studies comparing the use of high-dose ICS versus medium-dose ICS. Even
Furthermore, the use of macrolides for non-cystic fibrosis bronchiectasis treatment has become a common approach in recent years due to several characteristics such as their anti-inflammatory effects, ability to decrease mucus production, and well-known effect on Gram-positive cocci and atypical pathogens. Recent evidence shows that long-term treatment with macrolides, particularly azithromycin, significantly reduced the incidence of NCFB exacerbations while also improving quality of life.
To know more about non-cystic fibrosis bronchiectasis treatment guidelines, visit @ Non-Cystic Fibrosis Bronchiectasis Management
Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies and Key Companies
- Brensocatib: Insmed Incorporated/AstraZeneca
- Colistimethate sodium: Zambon
- CSL787:
CSL Behring - CHF 6333:
Chiesi Farmaceutici - BI 1291583:
Boehringer Ingelheim - AP-PA02: Armata Pharmaceuticals
- ARINA-1: Renovion
- S-1226: SolAeroMed
- HSK31858: Haisco Pharmaceutical
Learn more about the FDA-approved drugs for non-cystic fibrosis bronchiectasis @ Drugs for NCFB Treatment
Non-Cystic Fibrosis Bronchiectasis Market Dynamics
The dynamics of the non-cystic fibrosis bronchiectasis market are anticipated to be change in the coming years. Disease prevalence is increasing due to improved detection rates with advanced imaging techniques and increased awareness, further boosting the growth of non-cystic fibrosis bronchiectasis. Moreover, an improved understanding of disease pathophysiology aids in diagnosis and aids in the identification of novel target molecules for treatment development. Furthermore, large, positive, randomized controlled trials are currently in development to establish the standard of care for bronchiectasis patients. In addition, vaccines and monoclonal antibodies are partially useful, but more evidence-based studies are needed to prevent PA chronic colonization in bronchiectasis patients. Thus, the above-mentioned factors will propel the non-cystic fibrosis bronchiectasis market growth.
However, one of the major concerns in understanding the non-cystic fibrosis bronchiectasis market is the lack of evidence to validate many of the interventions used in the day-to-day management of NCFB. There are no global or regional consensus guidelines or any in
Moreover, because of this scarcity, there are gaps in understanding the current non-cystic fibrosis bronchiectasis treatment scenario. Certain studies, however, aid in extrapolating the current situation in which antibiotics remain the mainstay. Furthermore, disease-specific management is difficult because the etiology is often idiopathic. Despite advances in modern medicine, no validated biomarker for NCFB diagnosis, exacerbation assessment, or prognosis has been developed.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [ |
Base Year | 2019 |
Non-Cystic Fibrosis Bronchiectasis Market CAGR | 2.8 % |
Non-Cystic Fibrosis Bronchiectasis Market Size in 2022 | |
Key Non-Cystic Fibrosis Bronchiectasis Companies | Insmed Incorporated, AstraZeneca, Zambon, |
Key Pipeline Non-Cystic Fibrosis Bronchiectasis Therapies | Brensocatib, Colistimethate sodium, CSL787, |
Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report
- Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and emerging therapies
- Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Attribute Analysis of Emerging Non-Cystic Fibrosis Bronchiectasis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement
Discover more about non-cystic fibrosis bronchiectasis drugs in development @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials
Table of Contents
1. | Non-Cystic Fibrosis Bronchiectasis Market Key Insights |
2. | Non-Cystic Fibrosis Bronchiectasis Market Report Introduction |
3. | Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance |
4. | Non-Cystic Fibrosis Bronchiectasis Market Executive Summary |
5. | Disease Background and Overview |
6. | Non-Cystic Fibrosis Bronchiectasis Treatment and Management |
7. | Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population |
8. | |
9. | Non-Cystic Fibrosis Bronchiectasis Marketed Drugs |
10. | Non-Cystic Fibrosis Bronchiectasis Emerging Drugs |
11. | 7MM + |
12. | Non-Cystic Fibrosis Bronchiectasis Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Non-Cystic Fibrosis Bronchiectasis Market Drivers |
16. | Non-Cystic Fibrosis Bronchiectasis Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Non-Cystic Fibrosis Bronchiectasis Pipeline
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including
Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast
Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-cystic fibrosis bronchiectasis epidemiology in the 7MM, i.e.,
Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bronchiectasis companies, including
Bronchiectasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bronchiectasis companies, including
Bronchiectasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted bronchiectasis epidemiology in the 7MM, i.e.,
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @ Healthcare Consulting Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo:https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/non-cystic-fibrosis-bronchiectasis-market-to-showcase-growth-at-a-minimal-cagr-of-2-8-during-the-study-period-20192032-assesses-delveinsight-301787988.html
SOURCE
